Avirmax Biopharma doses first patient in phase I/IIa clinical trial of ABI-110

The first patient has been successfully dosed in the phase I/IIa clinical trial of ABI-110, Avirmax Biopharma's first gene therapy drug for the treatment of wet age-related macular degeneration (AMD) including polypoidal choroidal vasculopathy (PCV).

In the press release¹, Shawn Liu, PhD, Chief Executive Officer of Avirmax Biopharma Inc. highlighted this step forward, saying, "We are thrilled to announce this significant milestone in the clinical investigation of ABI-110. ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV."

ABI-110 has the potential to offer a more durable and effective solution than current treatment options by addressing the root causes of wet AMD at the genetic level.

According to the company, ABI-110, Avirmax Biopharma's proprietary gene therapy, utilizes an engineered capsid, AAV2.N54, to efficiently deliver therapeutic transgene to the macular retina. This approach aims to provide a long-lasting solution that goes beyond the limitations of current treatments. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV.1

Reference:

1. Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV. Avirmax Biopharma Inc. November 21, 2024. Accessed November 22, 2024. https://finance.yahoo.com/news/avirmax-biopharma-announces-first-patient-231500880.html